This pro-oncogenic role extends to other malignancies: PELP1 acts as a co-activator for the androgen receptor (AR) in prostate cancer and promotes proliferation and metastasis in ovarian and pancreatic cancers (Table 1). Here, AR is linked to prostate carcinoma.